Treating GVHD in Patients with Myelofibrosis Following Transplant
Tania Jain, MBBS, discusses the current treatment options for graft-versus-host-disease, a known complication of allogeneic stem cell transplant, which is the only curative treatment option for patients with myelofibrosis.
Tania Jain, MBBS, assistant professor of oncology, Division of Hematological Malignancies and Stem Cell Transplantation, Johns Hopkins University, discusses the current treatment options for graft-versus-host-disease (GVHD), a known complication of allogeneic stem cell transplant (SCT), which is the only curative treatment option for patients with myelofibrosis (MF).
There is a lot of work to be done in the treatment landscape for patients with MF. The only curative option for these patients is allogeneic SCT, and even drugs in the pipeline for MF do not offer anything curative at this time, says Jain.
GVHD is a known and unique complication of the allogenic SCT process. Acute GVHD, in particular, can present as a skin rash, upper/lower gastrointestinal symptoms, or liver disease. It is a result of potential tissue injury the happens from conditioning and results in increases of cytokine release, Jain says. Treatment is aimed to improve inflammation.
Connecting Spleen Volume Reduction to Survival Outcomes in MF
April 21st 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Read More
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
